AEON Biopharma, Inc. Research and Development Expense
AEON Biopharma, Inc. (AEON) reported Research and Development Expense of $2.94 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- AEON Biopharma, Inc. research and development expense for the quarter ending 2026-06-30 was $2.94M, a 176.13% increase year-over-year.
- AEON Biopharma, Inc. research and development expense for the quarter ending 2026-03-31 was $2.03M, a 146.55% increase year-over-year.
- AEON Biopharma, Inc. research and development expense for the quarter ending 2025-12-31 was $1.61M, a 47.02% decline year-over-year.
- AEON Biopharma, Inc. research and development expense for the quarter ending 2025-09-30 was $597.00K, a 38.58% decline year-over-year.
- AEON Biopharma, Inc. research and development expense for fiscal 2025 was $4.09M, a 71.13% decline from fiscal 2024.
- AEON Biopharma, Inc. research and development expense for fiscal 2024 was $14.18M.
- AEON Biopharma, Inc. research and development expense for fiscal 2022 was $34.75M.
| Period end | Research and Development Expense 1 month | Research and Development Expense 2 month | Research and Development Expense 2 month as first filed | Research and Development Expense 3 month | Research and Development Expense 5 month | Research and Development Expense 6 month | Research and Development Expense 7 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.94M 10-Q · filed 2026-08-12 | $4.97M 10-Q · filed 2026-08-12 | $6.58M derived: sum of 3 quarters · filed 2026-08-12 | $7.18M derived: sum of 4 quarters · filed 2026-08-12 | |||||
| 2026-03-31 | $2.03M 10-Q · filed 2026-05-14 | $3.64M derived: sum of 2 quarters · filed 2026-05-14 | $4.24M derived: sum of 3 quarters · filed 2026-05-14 | $5.30M derived: sum of 4 quarters · filed 2026-08-12 | |||||
| 2025-12-31 | $1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $2.21M derived: sum of 2 quarters · filed 2026-03-30 | $3.27M derived: sum of 3 quarters · filed 2026-08-12 | $4.09M 10-K · filed 2026-03-30 | |||||
| 2025-09-30 | $597.00K 10-Q · filed 2025-11-14 | $1.66M derived: sum of 2 quarters · filed 2026-08-12 | $2.48M 10-Q · filed 2025-11-14 | $5.52M derived: sum of 4 quarters · filed 2026-08-12 | |||||
| 2025-06-30 | $1.06M 10-Q · filed 2026-08-12 | $1.89M 10-Q · filed 2026-08-12 | $4.93M derived: sum of 3 quarters · filed 2026-08-12 | $5.90M derived: sum of 4 quarters · filed 2026-08-12 | |||||
| 2025-03-31 | $825.00K 10-Q · filed 2026-05-14 | $3.86M derived: sum of 2 quarters · filed 2026-05-14 | $4.83M derived: sum of 3 quarters · filed 2026-05-14 | $9.27M derived: sum of 4 quarters · filed 2026-05-14 | |||||
| 2024-12-31 | $3.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $4.01M derived: sum of 2 quarters · filed 2026-03-30 | $8.45M derived: sum of 3 quarters · filed 2026-03-30 | $14.18M 10-K · filed 2026-03-30 | |||||
| 2024-09-30 | $972.00K 10-Q · filed 2025-11-14 | $5.41M derived: sum of 2 quarters · filed 2025-11-14 | $11.14M 10-Q · filed 2025-11-14 | ||||||
| 2024-06-30 | $4.44M 10-Q · filed 2025-08-12 | $10.17M 10-Q · filed 2025-08-12 | |||||||
| 2024-03-31 | $5.73M 10-Q · filed 2025-05-14 | ||||||||
| 2023-12-31 | $13.24M 10-K · filed 2025-03-24 | ||||||||
| 2023-09-30 | $6.39M 10-Q/A · filed 2024-03-29 | ||||||||
| 2023-07-21 | $1.57M 10-Q · filed 2024-11-13 | $19.80M 10-K · filed 2025-03-24 | |||||||
| 2023-06-30 | $9.03M 10-Q · filed 2024-08-12 | $18.23M 10-Q · filed 2024-08-12 | $27.76M derived: sum of 3 quarters · filed 2024-08-12 | $35.24M derived: sum of 4 quarters · filed 2024-08-12 | |||||
| 2023-03-31 | $9.21M 10-Q · filed 2024-05-14 | $18.73M derived: sum of 2 quarters · filed 2024-05-14 | $26.21M derived: sum of 3 quarters · filed 2024-05-14 | ||||||
| 2022-12-31 | $9.53M derived: 10-K 12 month − 10-Q/A 9 month · filed 2024-03-29 | $17.01M derived: sum of 2 quarters · filed 2024-03-29 | $34.75M 10-K · filed 2024-03-29 | ||||||
| 2022-09-30 | $7.48M 10-Q/A · filed 2024-03-29 | $25.23M 10-Q/A · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |